Carregant...
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer
Programmed death-1 (PD-1) and its ligand are part of the immune checkpoint pathway that down-regulates effector T cells in immune response, thereby causing immune suppression. The PD-1/programmed death-ligand 1 (PD-L1) pathway can be blocked by antibodies to reverse tumor-mediated immunosuppression....
Guardat en:
| Publicat a: | J Gynecol Oncol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5540723/ https://ncbi.nlm.nih.gov/pubmed/28657225 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2017.28.e64 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|